How certain bacteria use a receptor on immune cells to cause infections
Virulent Rickettsia species utilize the CD300f phosphatidylserine-binding receptor on macrophages for host colonization and pathogenesis
This study is exploring how certain harmful bacteria interact with immune cells in our body, aiming to find out how these bacteria get inside the cells and how we might develop better treatments for infections caused by them, which could help patients in the future.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10674996 on NIH RePORTER |
What this research studies
This research investigates how virulent Rickettsia species, which are bacteria that can cause serious infections, interact with immune cells called macrophages. The study focuses on understanding the mechanisms by which these bacteria are engulfed by macrophages, specifically looking at a receptor known as CD300f that may facilitate this process. By identifying the specific components on the bacteria that trigger this interaction, the research aims to uncover new insights that could lead to better treatments for infections caused by Rickettsia. Patients may benefit from improved therapeutic strategies as a result of this work.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been diagnosed with Rickettsia infections or are at high risk of exposure to these bacteria.
Not a fit: Patients with infections caused by other types of bacteria or those who are not at risk for Rickettsia infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective treatments for Rickettsia infections.
How similar studies have performed: Previous research has shown success in understanding bacterial interactions with immune cells, but this specific approach to Rickettsia is relatively novel.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Voss, Oliver — University of Maryland Baltimore
- Study coordinator: Voss, Oliver
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.